EUCTR2005-002145-39-IS进行中（未招募）1 期
An open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of patients with history of myocardial infarction (positive or negative for FLAP or LTA4 hydrolase haplotypes) - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age 40 to 75.
- •2.Serum CRP levels of =2.0.
- •3.Diagnosis of CAD (based on interview, medication history and physical examination) and history of MI.
- •4.Postmenopausal women or women of childbearing potential willing to use two adequate barrier methods of contraception or willing to abstain from heterosexual activity throughout the study, starting with Visit 1 and for 14 days after the last dose of study medication. Refer to section 13.5.2 for information on adequate contraceptive methods. All women of childbearing potential must have a negative urine pregnancy test at Visit 1.
- •Note: Women of childbearing potential are defined as premenopausal, not having had surgical sterilisation (hysterectomy or bilateral tubal ligation or bilateral oophorectomy). Postmenopausal status is defined as =45 years of age with >2 years since last menses.
- •5.Understanding of the study procedures and agreement to participate in the study by giving written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Congestive heart failure (CHF).
- •2.Any experimental treatment within 2 months of screening or planned for the following 2 months.
- •3.Acute CV event (such as ACS, MI or stroke) within 1 month prior to enrolment.
- •4.Elevated CPK above 3 fold upper normal limit (UNL). Other liver function tests and kidney function tests above 1.5 fold upper normal limit.
- •5.Immunocompromised subjects, including subjects known to be HIV positive or with malignant disease and/or on chronic immunosuppressive therapy.
- •6.Subjects known to have positive serology results for HBsAg, HCV Ab.
- •7.Treatment with immunosuppressive cytotoxic drugs or corticosteroids within 6 weeks or during conduct of study.
- •8.Major surgery within 6 weeks prior to enrolment.
- •9.Any other major intercurrent illness and other condition, which, in the investigator’s judgement, will interfere with the subject’s participation in this study.
- •10.Subjects not willing to return for follow-up or with known history of non-compliance.
- •11.Subjects not willing to adhere to restrictions of alcohol use for the duration of the study (=3 units of alcohol/day or =15 units of alcohol/week and no alcohol for 48 hours prior to clinic visits).
- •Note: A unit of alcohol is defined as a single measure of spirit (25 ml), one small glass of sherry or fortified spirit (50 ml), one small glass of wine (125 ml) or one small regular strength beer (330 ml, 4-5%).
- •12.Pregnant or lactating women.
- •13.Poor mental function or any other reason to expect difficulty in complying with the requirements of the study.
研究者
相似试验
进行中（未招募）
1 期
An open label, dose-ranging study to establish the tolerability of Alpharen™ in haemodialysis subjects with hyperphosphataemia. - ACT 3EUCTR2006-004735-30-GBIneos Healthcare Ltd60
进行中（未招募）
1 期
A single-site, open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of FLAP and/or LTA4 hydrolase haplotype positive patients with coronary artery disease. - N/AEUCTR2004-004980-30-ISdeCODE genetics ehf.75
招募中
1 期
Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumorsCTIS2024-511884-27-00Oxford Biotherapeutics Limited170
招募中
不适用
A randomized, open-label, and single-dose study to evaluate the safety and the pharmacokinetics after concurrent administration of UIC202007 and UIC202008 in healthy adult subjectsKCT0005901Korea United Pharm30
进行中（未招募）
1 期
An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit - BI 894999 first in human dose finding study in advanced malignanciesAdvanced, unresectable and/or metastatic solid tumours, which have failed with conventional treatment or for which no therapy of proven efficacy exists, or in patients who are not amenable to standard therapies and patients with diffuse large B-cell lymphoma (DLBCL) for whom there are limited or no standard treatment options availableMedDRA version: 20.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10010029Term: Colorectal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10078295Term: NUT midline carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001111-12-BESCS Boehringer Ingelheim Comm.V158